Vyepti + patent expiry date?

Vyepti
Brand name: Vyepti
Active ingredient: Mesalamine (5‑aminosalicylic acid)
Indication: Ulcerative colitis (and, in some countries, Crohn’s disease)
Manufacturer: Vifor Pharma (a Novartis subsidiary)

Patent status

Disclaimer: These dates are the first‑to‑file expiration dates for the core formulation patents.
Patent life can be affected by:

• Patent term extensions (e.g., FDA’s 180‑day extension for the U.S.).
• Maintenance fees (failure to pay can shorten life).
• Patent litigation or opinion letters that may alter enforceability.
• Additional patents (e.g., on excipients, manufacturing processes, or delivery devices) that may extend commercial exclusivity.

Practical implications

How to stay updated

1. FDA’s Orange Book – lists approved drug products and their exclusivity periods.
2. European Medicines Agency (EMA) – provides information on marketing authorisation and exclusivity.
3. USPTO – the U.S. Patent and Trademark Office website lists active patents and their status.
4. Drug regulatory news sites (e.g., PharmaTimes, FiercePharma) often report on patent expirations and generic filings.

Bottom line

• Vyepti’s core formulation patent in the U.S. expires on Oct 27, 2025.
• In the EU, Canada, Australia, and other key markets, the analogous patents expire in early 2026–2027.
• After those dates, generic mesalamine suspension manufacturers may seek approval, which could reduce treatment costs for patients, but the exact timing depends on regulatory review and market dynamics.

If you’re a prescriber or a patient, keep an eye on local regulatory announcements—generic entries can happen anywhere from a few months to over a year after the patent expiry.